ArticleInflammopharmacology2025
Anti-colitic effects of Oldenlandia umbellata L. through NF-κB pathway inhibition in a DSS-induced mouse model.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is an inflammatory bowel disease marked by epithelial barrier dysfunction and hyperactivation of immune signaling, particularly in the NF-κB pathway. Conventional therapies are limited by side effects and relapse risk, highlighting the need for safer, plant-based interventions. Oldenlandia umbellata L., a traditional herb, has demonstrated anti-inflammatory potential but remains underexplored in gastrointestinal disorders.
objectiveThis study investigates the therapeutic efficacy of a methanolic extract of O.umbellata L. (MEOU) in a dextran sulfate sodium (DSS)-induced mouse model of colitis, focusing on its effects on clinical symptoms, histopathology, intestinal permeability, cytokine expression, and NF-κB signaling.
methodsAcute colitis was induced in BALB/c mice with 5% DSS for 7 days, followed by oral treatment with MEOU (100, 200 or 400 mg/kg) and prednisolone (5 mg/kg) for another 7 days. Clinical parameters (body weight, Disease Activity Index (DAI), colon and spleen morphology, and histopathology were evaluated. Intestinal permeability was measured by FITC-dextran assay, while TNF-α, IL-6 mRNA levels, and NF-κB p65 protein levels were analyzed by RT-qPCR and Western blot, respectively.
resultsMEOU significantly attenuated weight loss, reduced DAI scores, and reversed colon shortening and splenomegaly in a dose-dependent manner. Histological analysis revealed preserved mucosal structure and reduced inflammatory infiltration. FITC-dextran assays confirmed improved barrier integrity. Molecular analyses showed that MEOU downregulated pro-inflammatory cytokines and suppressed NF-κB p65 activation.
conclusionMEOU exhibits potent anti-colitic activity through anti-inflammatory and barrier-protective mechanisms by NF-κB pathway inhibition, supporting its potential as a plant-based therapeutic for UC.
Indexed as
Identifiers
40549321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.